Form 4: Revolution Medicines Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 2,123 shares of common stock on March 18, 2024, to cover tax obligations related to vesting restricted stock units.
Summary
- On March 18, 2024, Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 2,123 shares of the company's common stock.
- The sale was executed at a price of $31.5832 per share.
- This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2023, to cover tax withholding obligations upon the vesting of restricted stock units (RSUs).
- Following the transaction, Kelsey directly owns 270,909 shares, which includes 104,550 RSUs.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (stock sale for tax obligations) and does not contain any information that would significantly impact investor sentiment positively or negatively.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives and are generally viewed as routine transactions.
Key Dates
| Date | Description |
|---|---|
| 05/31/2023 | Date of adoption of Rule 10b5-1 trading plan. |
| 03/18/2024 | Date of stock sale transaction. |
| 03/20/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.